Involving a team with extensive academic experience in molecular virology, drug resistance, cancer therapies, and medicinal chemistry, Quercus Molecular Design (QMD) was established to leverage decades of research experience and over $20 million of federal research support in the Weller and Wright laboraties at the University of Connecticut to discover and develop small molecule inhibitors to treat infectious diseases and cancer. An innovative strategy has been crafted by which Quercus Molecular Design (QMD) will address discovery of small molecule inhibitors that simultaneously inhibit (or target) two or more essential proteins to treat infectious disease and cancer targets. This multi-targeting approach is expected to both enhance potency and slow the onset of resistance. The firm's out-of-the-box project involves targeting anti-viral agents to inhibit Herpesevirus infections,
